<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome - Naheed, B - 2017 | Cochrane Library</title> <meta content="Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome - Naheed, B - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010503.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome - Naheed, B - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010503.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010503.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome" name="citation_title"/> <meta content="Bushra Naheed" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="b.naheed@keele.ac.uk" name="citation_author_email"/> <meta content="Jan Herman Kuiper" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="Olalekan A Uthman" name="citation_author"/> <meta content="Division of Health Sciences, Warwick Medical School, The University of Warwick" name="citation_author_institution"/> <meta content="Fidelma O'Mahony" name="citation_author"/> <meta content="University Hospitals of North Midlands" name="citation_author_institution"/> <meta content="Patrick Michael Shaughn O'Brien" name="citation_author"/> <meta content="Keele University Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD010503.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010503.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010503.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010503.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Drug Implants; Drug Therapy, Combination; Estrogens [*administration &amp; dosage, adverse effects]; Luteal Phase; Premenstrual Dysphoric Disorder [drug therapy]; Premenstrual Syndrome [*drug therapy]; Progestins; Randomized Controlled Trials as Topic; Transdermal Patch" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010503.pub2&amp;doi=10.1002/14651858.CD010503.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010503\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010503\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fr","zh_HANS","fa","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010503.pub2",title:"Non\\u2010contraceptive oestrogen\\u2010containing preparations for controlling symptoms of premenstrual syndrome",firstPublishedDate:"Mar 3, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010503.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010503.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010503.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010503.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010503.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010503.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010503.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010503.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010503.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010503.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3977 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010503.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0138"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0072"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/appendices#CD010503-sec-0143"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/table_n/CD010503StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/table_n/CD010503StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#CD010503-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bushra Naheed</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#CD010503-cr-0003">Jan Herman Kuiper</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#CD010503-cr-0004">Olalekan A Uthman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#CD010503-cr-0005">Fidelma O'Mahony</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information#CD010503-cr-0006">Patrick Michael Shaughn O'Brien</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information/en#CD010503-sec-0152">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010503.pub2">https://doi.org/10.1002/14651858.CD010503.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010503-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010503-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010503-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010503-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010503-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010503-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010503-abs-0001" lang="en"> <section id="CD010503-sec-0001"> <h3 class="title" id="CD010503-sec-0001">Background</h3> <p>Premenstrual syndrome (PMS) is a psychological and somatic disorder of unknown aetiology, with symptoms typically including irritability, depression, mood swings, bloating, breast tenderness and sleep disturbances. About 3% to 10% of women who experience these symptoms may also meet criteria for premenstrual dysphoric disorder (PMDD). PMS symptoms recur during the luteal phase of the menstrual cycle and reduce by the end of menstruation. PMS results from ovulation and may be due to ovarian steroid interactions relating to neurotransmitter dysfunction. Premenstrual disorders have a devastating effect on women, their families and their work. </p> <p>Several treatment options have been suggested for PMS, including pharmacological and surgical interventions. The treatments thought to be most effective tend to fall into one of two categories: suppressing ovulation or correcting a speculated neuroendocrine anomaly. </p> <p>Transdermal oestradiol by patch, gel or implant effectively stops ovulation and the cyclical hormonal changes which produce the cyclical symptoms. These preparations are normally used for hormone therapy and contain lower doses of oestrogen than found in oral contraceptive pills. A shortened seven‐day course of a progestogen is required each month for endometrial protection but can reproduce premenstrual syndrome‐type symptoms in these women. </p> </section> <section id="CD010503-sec-0002"> <h3 class="title" id="CD010503-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of non‐contraceptive oestrogen‐containing preparations in the management of PMS. </p> </section> <section id="CD010503-sec-0003"> <h3 class="title" id="CD010503-sec-0003">Search methods</h3> <p>On 14 March 2016, we searched the following databases: the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register; Cochrane Central Register of Studies (CRSO); MEDLINE; Embase; PsycINFO; CINAHL; ClinicalTrials.gov; metaRegister of Controlled trials (mRCT); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal. In addition, we checked the reference lists of articles retrieved. </p> </section> <section id="CD010503-sec-0004"> <h3 class="title" id="CD010503-sec-0004">Selection criteria</h3> <p>We included published and unpublished randomized placebo or active controlled trials on the efficacy of the use of non‐contraceptive oestrogen‐containing preparations in the management of premenstrual syndrome in women of reproductive age with PMS diagnosed by at least two prospective cycles without current psychiatric disorder. </p> </section> <section id="CD010503-sec-0005"> <h3 class="title" id="CD010503-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed risk of bias, extracted data on premenstrual symptoms and adverse effects and entered data into Review Manager 5 software. Where possible, intention‐to‐treat or modified intention‐to‐treat analysis was used. Studies were pooled using a fixed‐effect model, analysing cross‐over trials as parallel trials. Standardised mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for premenstrual symptom scores. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. The overall quality of the evidence was assessed using the GRADE working group methods. </p> </section> <section id="CD010503-sec-0006"> <h3 class="title" id="CD010503-sec-0006">Main results</h3> <p>The search resulted in 524 potentially relevant articles. Five eligible randomized controlled trials (RCTs) were identified (305 women). Trials using oral tablets, transdermal patches and implants were identified. No trial used gels. </p> <p>One small cross‐over trial (11 women, effective sample size 22 women considering cross‐over trials) compared oral luteal‐phase oestrogen versus placebo. Data were very low quality and unsuitable for analysis, but study authors reported that the intervention was ineffective and might aggravate the symptoms of PMS. They also reported that there were no adverse events. </p> <p>Three studies compared continuous oestrogen with progestogen versus placebo (with or without progestogen). These trials were of reasonable quality, although with a high risk of attrition bias and an unclear risk of bias due to potential carry‐over effects in two cross‐over trials. Continuous oestrogen had a small to moderate positive effect on global symptom scores (SMD −0.34, 95% CI −0.59 to −0.10, P = 0.005, 3 RCTs, 158 women, effective sample size 267 women, I² = 63%, very low quality evidence). The evidence was too imprecise to determine if the groups differed in withdrawal rates due to adverse effects (RR 0.64, 95% CI 0.26 to 1.58, P = 0.33, 3 RCTs, 196 women, effective sample size 284 women, I² = 0%, very low quality evidence). Similarly, the evidence was very imprecise in measures of specific adverse events, with large uncertainties around the true value of the relative risk. None of the studies reported on long‐term risks such as endometrial cancer or breast cancer. </p> <p>One study compared patch dosage (100 vs 200 µg oestrogen, with progestogen in both arms) and had a high risk of performance bias, detection bias and attrition bias. The study did not find evidence that dosage affects global symptoms but there was much uncertainty around the effect estimate (SMD −1.55, 95% CI −8.88 to 5.78, P = 0.68, 1 RCT, 98 women, very low quality evidence). The evidence on rates of withdrawal for adverse events was too imprecise to draw any conclusions (RR 0.70, 95% CI 0.34 to 1.46, P = 0.34, 1 RCT, 107 women, low‐quality evidence). However, it appeared that the 100 µg dose might be associated with a lower overall risk of adverse events attributed to oestrogen (RR 0.51, 95% Cl 0.26 to 0.99, P = 0.05, 1 RCT, 107 women, very low quality evidence) with a large uncertainty around the effect estimate. </p> <p>The overall quality of the evidence for all comparisons was very low, mainly due to risk of bias (specifically attrition), imprecision, and statistical and clinical heterogeneity. </p> </section> <section id="CD010503-sec-0007"> <h3 class="title" id="CD010503-sec-0007">Authors' conclusions</h3> <p>We found very low quality evidence to support the effectiveness of continuous oestrogen (transdermal patches or subcutaneous implants) plus progestogen, with a small to moderate effect size. We found very low quality evidence from a study based on 11 women to suggest that luteal‐phase oral unopposed oestrogen is probably ineffective and possibly detrimental for controlling the symptoms of PMS. A comparison between 200 µg and 100 µg doses of continuous oestrogen was inconclusive with regard to effectiveness, but suggested that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the identified studies were too small to provide definite answers. Moreover, no included trial addressed adverse effects that might occur beyond the typical trial duration of 2‐8 months. This suggests the choice of oestrogen dose and mode of administration could be based on an individual woman’s preference and modified according to the effectiveness and tolerability of the chosen regimen. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010503-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010503-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010503-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010503-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010503-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010503-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010503-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ro#CD010503-abs-0014">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010503-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010503-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010503-abs-0004" lang="en"> <h3>Oestrogen for premenstrual syndrome</h3> <p><b>Review question</b> </p> <p>Oestrogen is widely used to suppress ovulation, mainly as a contraceptive. This is the first systematic review aiming to evaluate the effectiveness and safety of non‐contraceptive oestrogen‐containing preparations (oral, patch, implant and gel) in controlling symptoms of premenstrual syndrome (PMS). </p> <p><b>Background</b> </p> <p>PMS is characterised by a range of physical, psychological and behavioural symptoms that are not due to any organic disease, and that occur during the luteal phase (second half) of the menstrual cycle and disappear at the onset of menstruation. It is now thought that the condition is due to complex interactions between ovarian steroids and neurotransmitters. A clinical diagnosis requires that the symptoms are confirmed by prospective recording for at least two menstrual cycles and that they cause substantial distress or impairment to daily life (e.g. work, school, social activities, hobbies, interpersonal relationships). </p> <p><b>Study characteristics</b> </p> <p>The review identified 524 potentially relevant articles. Only five randomized controlled trials met our inclusion criteria, and these compared oestrogen with placebo in a total of 305 women who were clinically diagnosed with PMS. </p> <p><b>Key results</b> </p> <p>We found very low quality evidence to suggest that oral unopposed oestrogen given in the luteal phase of the menstrual cycle is probably ineffective for controlling the symptoms of PMS and may even make them worse. There was very low quality evidence to support the effectiveness of continuous oestrogen (in the form of transdermal patches or subcutaneous implants) plus progestogen, with a small to moderate effect size. A comparison between 200 microgram and 100 microgram doses of continuous oestrogen was inconclusive with regard to effectiveness but suggested that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the identified studies were too small to provide definite answers. Moreover, none of the included trials addressed adverse effects that might occur beyond the typical trial duration of 2 to 8 months. This suggests the choice of oestrogen dose and mode of administration could be based on an individual woman’s preference and modified according to the effectiveness and tolerability of the chosen regimen. </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of the evidence for all comparisons was graded as very low, mainly due to risk of bias in the included studies, imprecision (due to small sample sizes) and differences between the studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010503-sec-0138" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010503-sec-0138"></div> <h3 class="title" id="CD010503-sec-0139">Implications for practice</h3> <section id="CD010503-sec-0139"> <p>We found very low quality evidence to support the effectiveness of continuous oestrogen (in the form of transdermal patches or subcutaneous implants) plus progestogen, with a small to moderate effect size. We also found very low quality evidence from a single study of 11 women to suggest that luteal‐phase unopposed oral oestrogen is probably ineffective and possibly detrimental for controlling the symptoms of PMS. A comparison between 200 µg and 100 µg doses of continuous oestrogen was inconclusive with regard to effectiveness, but suggested that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the identified studies were too small to provide definite answers. Moreover, none of the included trials addressed adverse effects that might occur beyond the typical trial duration of 2 to 8 months. This suggests the choice of oestrogen dose and mode of administration could be based on an individual woman’s preference and modified according to the effectiveness and tolerability of the chosen regimen. </p> </section> <h3 class="title" id="CD010503-sec-0140">Implications for research</h3> <section id="CD010503-sec-0140"> <p>This review found very low quality evidence that continuous oestrogen may be an effective treatment strategy for PMS. However, all trials comparing continuous oestrogen to placebo were published at least 15 years before this review and may have shown a lesser effectiveness due to unwanted progestagenic side effects. This can perhaps be overcome by using local progestogen in the form of an LNG‐IUS or using a different type of progestogen such as drospirenone. Further research comparing various methods of administering progestogens may enable continuous oestrogen to become one of the most effective treatment options for the common condition of PMS. Our review found low‐quality evidence that continuous oestrogen may be considered effective though they are not widely used outside the UK. New and larger randomized clinical trials are justified, in particular to investigate the efficacy and safety of oestrogen in combination with the currently used forms of endometrial protection such as LNG‐IUS or different forms of progestogen. New trials should be based on established diagnostic criteria of the International Society for the Study of Premenstrual Disorders (ISPMD), include a power analysis, have a parallel design and report full statistical information with standard deviations for all continuous outcomes to facilitate their inclusion in meta‐analyses. </p> <p>Future research should focus on:</p> <p> <ul id="CD010503-list-0012"> <li> <p>direct comparisons between different oestrogen administration regimens, including their safety, tolerability and effectiveness for overall symptoms and for specific symptom types over long‐term follow‐up; </p> </li> <li> <p>recruiting an adequate number of participants and providing treatment for a sufficient duration and follow up; </p> </li> <li> <p>developing an agent that provides endometrial protection without regenerating premenstrual symptoms, for example selective progesterone receptor modulators or intrauterine progestogens; and </p> </li> <li> <p>studies designed according to the established diagnostic criteria of International Society for the Study of Premenstrual Disorders. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010503-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010503-sec-0036"></div> <div class="table" id="CD010503-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oestrogen in combination with progestogen (sequential or continuous) compared to placebo for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oestrogen in combination with progestogen (sequential or continuous) compared to placebo. for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> continuous oestrogen (implant or patch) plus progestogen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen in combination with progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom scores</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The difference in the mean change from baseline in symptom scores suggested a small to moderate benefit in the oestrogen group (SMD 0.27 lower, 95% CI 0.47 lower to 0.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 women, effective sample size 267 women considering cross‐over trials<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (20 to 122) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/> (0.26 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 women, effective sample size 284 women considering cross‐over trials<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific adverse events</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two RCTs (total 206 women) assessed one or more of nine specific adverse events and all findings were inconclusive. Events assessed were bleeding, breast tenderness, headache, nausea, weight gain, dysmenorrhoea, skin irritation, skin reaction and skin pigmentation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Includes cross‐over trial(s), with cross‐over at 3 or 4 months </p> <p><sup>2</sup>Downgraded one level for serious risk of bias: poor reporting of methods in one study and/or high attrition, includes one or more cross‐over studies with unclear risk of carry‐over effects </p> <p><sup>3</sup>Downgraded one level for serious inconsistency: I² = 63% </p> <p><sup>4</sup>Downgraded one level for questionable applicability: one of the studies administered progestogen in both arms </p> <p><sup>5</sup> Downgraded one level for serious imprecision: very few events and/or wide confidence intervals compatible with benefit in one or both arms or with no clinically meaningful effect </p> <p><sup>6</sup>Downgraded two levels for very serious imprecision: very few events and/or very wide confidence intervals compatible with benefit in one or both arms or with no clinically meaningful effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010503-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> luteal‐phase oestrogen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global symptoms of PMS</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The study authors reported that luteal‐phase oestrogen had a large negative effect on overall symptoms compared to placebo (P &lt; 0.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 women, effective sample size 22 women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events:</p> <p>withdrawal due to adverse events</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No withdrawals occurred in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 women, effective sample size 22 women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific adverse events</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The study authors reported that "no significant adverse events were encountered".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 women,effective sample size 22<br/> women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Cross‐over study with 11 women, but analyzed as a parallel trial (hence 22 participants). Women had 3 cycles in each arm. </p> <p><sup>2</sup> Downgraded two levels for very serious risk of bias: poor reporting of methods, no data suitable for analysis as used non‐validated scales </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision: tiny sample size (but no further downgrading possible) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010503-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> oestrogen 100 µg patch plus progestogen<br/> <b>Comparison:</b> oestrogen 200 µg patch plus progestogen </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 200 µg patch plus progestogen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen 100 µg patch plus progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms score: Premenstrual Daily Questionnaire (PDQ)</p> <p>Scale from 0 to 30, with a higher score indicating a worse outcome</p> <p>over 8 months follow up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The difference in the change from baseline in the PDQ score was too imprecise to determine whether dosage had an effect on global symptoms (MD 1.55 lower, 95% CI 8.88 lower to 5.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ withdrawal rates</p> <p>over 8 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (87 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.34 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ specific side effects attributed to oestrogen</p> <p>over 8 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (92 to 349) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.51<br/> (0.26 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious risk of bias: unblinded, high attrition </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision: wide confidence intervals consistent with benefit in one or both arms or with no clinically meaningful effect from the intervention (however no further downgrading possible) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010503-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010503-sec-0037"></div> <section id="CD010503-sec-0038"> <h3 class="title" id="CD010503-sec-0038">Description of the condition</h3> <p>Premenstrual syndrome (PMS) is a disorder affecting large numbers of women, characterised by a set of symptoms that occur during the second half (luteal phase) of the menstrual cycle. Symptoms disappear by the end of menstruation and do not recur before ovulation, giving a symptom‐free interval of at least one week in the first half (follicular phase) of the menstrual cycle. PMS is cyclical and occurs in most menstrual cycles (<a href="./references#CD010503-bbs2-0031" title="O'BrienS , RapkinA , DennersteinL , NevatteT . Diagnosis and Management of Premenstrual Syndrome. BMJ2011;342:d2994. ">O'Brien 2011</a>). PMS is marked by a variety of emotional, physical, and behavioural symptoms. The symptoms typically include irritability, depression, mood swings, bloating, breast tenderness and sleep disturbances (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>; <a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>; <a href="./references#CD010503-bbs2-0030" title="O'BrienP , IsmailK , DimmockP . Premenstrual syndrome. In: ShawR , SoutterW , StantonS editor(s). Gynaecology. 3rd Edition. London: Churchill Livingston, 2003:401‐11. ">O'Brien 2003</a>; <a href="./references#CD010503-bbs2-0032" title="PanayN . Premenstrual syndrome: Making sense of the options. Pulse2004;65(8):50‐4. ">Panay 2005</a>). A severe form of PMS is known as premenstrual dysphoria or premenstrual dysphoric disorder (PMDD) and was previously known as late luteal phase dysphoric disorder (<a href="./references#CD010503-bbs2-0031" title="O'BrienS , RapkinA , DennersteinL , NevatteT . Diagnosis and Management of Premenstrual Syndrome. BMJ2011;342:d2994. ">O'Brien 2011</a>); it causes significant distress and interferes with normal functioning. The symptoms of PMS and PMDD are similar but the level of impairment is greater in PMDD. Studies have reported that as many as 85% of menstruating women have experienced at least one symptom of PMS (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>; <a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>). In about 3% to 10% of women, the symptoms have adverse effects on activities of daily living and may affect their interpersonal relationships (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>; <a href="./references#CD010503-bbs2-0020" title="HalbreichU , BorensteinJ , PearlsteinT , KahnLS . The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology2003;28(Suppl 3):1‐23. ">Halbreich 2003</a>; <a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>; <a href="./references#CD010503-bbs2-0030" title="O'BrienP , IsmailK , DimmockP . Premenstrual syndrome. In: ShawR , SoutterW , StantonS editor(s). Gynaecology. 3rd Edition. London: Churchill Livingston, 2003:401‐11. ">O'Brien 2003</a>; <a href="./references#CD010503-bbs2-0032" title="PanayN . Premenstrual syndrome: Making sense of the options. Pulse2004;65(8):50‐4. ">Panay 2005</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>). About 1.5 million women in the United Kingdom experience such severe PMS that it greatly reduces their quality of life. Studies have demonstrated deterioration in work effectiveness and cognitive function in women with PMS compared to women without PMS (<a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>; <a href="./references#CD010503-bbs2-0032" title="PanayN . Premenstrual syndrome: Making sense of the options. Pulse2004;65(8):50‐4. ">Panay 2005</a>). </p> <p>The precise causation or aetiology of PMS remains unclear. No significant racial or ethnic differences have been shown to exist (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>). PMS tends to be more severe among women aged 25 to 35 years old (<a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>). There appears to be a genetic link with PMS risk; monozygotic twins are twice as likely to suffer from PMS as dizygotic twins (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>). Similarly, daughters of affected mothers have a 70% greater chance of experiencing PMS than those with unaffected mothers (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>). Past history of depressive illness is another significant reported risk factor for PMS (<a href="./references#CD010503-bbs2-0024" title="JohnsonS . The epidemiology of premenstrual syndrome. Primary Psychiatry2004;11(2):27‐32. ">Johnson 2004</a>; <a href="./references#CD010503-bbs2-0025" title="KaurG , GonsalvesL , ThackerHL . Premenstrual dysphoric disorder: a review for the treating practitioner. Cleveland Clinic Journal of Medicine2004;71(4):303‐5, 312‐3, 317‐8 passim. ">Kaur 2004</a>). Previous publications have variably hypothesised that PMS may be associated with excess oestrogen, a deficiency of progesterone or changes in the ratio of oestrogen and progesterone (<a href="./references#CD010503-bbs2-0017" title="Gianetto‐BerrutiA , FeylesV . Premenstrual syndrome. Minerva Ginecologica2002;54(2):85‐95. ">Gianetto‐Berruti 2002</a>). Attempts to treat the symptoms of PMS by addressing the ratio of oestrogen and progesterone through administering progestogen have not demonstrated benefits (<a href="./references#CD010503-bbs2-0016" title="FordO , LethabyA , RobertsH , MolBW . Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD003415.pub2] ">Ford 2012</a>). It is now thought that the condition is due to complex interactions between ovarian steroids and neurotransmitters (<a href="./references#CD010503-bbs2-0033" title="RapkinAJ , KuoJ . The Premenstrual Syndromes. In: O’BrienPMS , RapkinA , SchmidtP editor(s). PMS &amp; PMDD. London: Informa Healthcare, 2007:69‐83. ">Rapkin 2007</a>). Treatment of PMS symptoms by using selective serotonin reuptake inhibitors (SSRIs), which alter the balance of serotonin (a neurotransmitter), has been found effective but comes with dose‐dependent adverse effects (<a href="./references#CD010503-bbs2-0027" title="MarjoribanksJ , BrownJ , O’BrienPMS , WyattK . Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD001396.pub3] ">Marjoribanks 2013</a>). Although much has been written on diagnostic criteria over the past 30 years, there is no true consensus on which technique is acceptable. A clinical diagnosis requires symptoms to be confirmed by prospective recording for at least two menstrual cycles and that symptoms cause substantial distress or impairment to daily life (e.g. work, school, social activities, hobbies, interpersonal relationships) (<a href="./references#CD010503-bbs2-0012" title="ACOG . ACOG practice bulletin: premenstrual syndrome. International Journal of Gynaecology and Obstetrics2001;73:183‐91. ">ACOG 2001</a>; <a href="./references#CD010503-bbs2-0031" title="O'BrienS , RapkinA , DennersteinL , NevatteT . Diagnosis and Management of Premenstrual Syndrome. BMJ2011;342:d2994. ">O'Brien 2011</a>). Individual studies have used idiosyncratic techniques, this being true particularly for older studies. Typically these methods have included visual analogue scales, categorical scales such as Moos Menstrual Distress Questionnaire, Calendar of Premenstrual Experiences and the Daily Record of Severity of Problems. There remains no established consensus but the Daily Record of Severity of Problems has been used in most recent publications. </p> </section> <section id="CD010503-sec-0039"> <h3 class="title" id="CD010503-sec-0039">Description of the intervention</h3> <p>Oestrogen therapy has been proposed as a method for management of PMS through its ability to suppress ovulation and the subsequent endocrine changes of the cycle. Oestrogen can be delivered as oral tablets, transdermal patches, implants, vaginal pessaries, gels and creams. Various doses and regimens of continuous oestrogen have been used. Because the aim is to suppress ovulation, the rationale for intermittent use is not clear. The oestrogens which have been used and studied in the management of PMS include mainly oestradiol in the form of transdermal patches or subcutaneous implants to suppress ovulation in controlled studies (<a href="./references#CD010503-bbs2-0019" title="GreenLJ , O’BrienPMS , PanayN , Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol2017;124:e73‐e105. ">Green 2017</a>). Both routes of administering oestradiol appear to show positive effects for treating mental and physical symptoms (<a href="./references#CD010503-bbs2-0019" title="GreenLJ , O’BrienPMS , PanayN , Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol2017;124:e73‐e105. ">Green 2017</a>). To prevent endometrial hyperplasia, cyclical progestogens are given to ensure a regular withdrawal bleed. The potential oestrogens which may suppress ovulation include natural and synthetic oestrogens. </p> </section> <section id="CD010503-sec-0040"> <h3 class="title" id="CD010503-sec-0040">How the intervention might work</h3> <p>Though many theories have been proposed, the exact pathway and definitive aetiology of PMS is unknown (<a href="./references#CD010503-bbs2-0030" title="O'BrienP , IsmailK , DimmockP . Premenstrual syndrome. In: ShawR , SoutterW , StantonS editor(s). Gynaecology. 3rd Edition. London: Churchill Livingston, 2003:401‐11. ">O'Brien 2003</a>; <a href="./references#CD010503-bbs2-0019" title="GreenLJ , O’BrienPMS , PanayN , Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol2017;124:e73‐e105. ">Green 2017</a>). PMS is probably related to ovulation as symptoms do not occur before the onset of puberty, during pregnancy or after menopause. PMS can occur in the absence of menstruation and it therefore can occur after hysterectomy (with ovarian conservation) and after endometrial ablation where ovarian function is unaffected (<a href="./references#CD010503-bbs2-0023" title="O'BrienPMS , BäckströmT , BrownC , DennersteinL , EndicottJ , EppersonCN , et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Archives of Women's Mental Health2011;14(1):13. ">ISPMD 2011</a>). This knowledge has led to the use of several ovulation‐suppressing drugs. The nature of some of these drugs limits their long‐term use because of associated safety issues, thereby also limiting their success. For example, gonadotrophin‐releasing hormone analogues (GnRH agonists) and danazol have both demonstrated efficacy in alleviating several premenstrual symptoms (<a href="./references#CD010503-bbs2-0019" title="GreenLJ , O’BrienPMS , PanayN , Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol2017;124:e73‐e105. ">Green 2017</a>). Though effective, the value of danazol is limited because of its androgenic side effects and so it is rarely used on a long term basis. GnRH is very effective but long‐term use is limited by consequences of the resulting oestrogen‐deficient state.   </p> <p>Controlled trials have demonstrated that 17‐β‐oestradiol combined with cyclical progestogen (for regular withdrawal periods and to prevent endometrial hyperplasia) administered as an implant or patch may be effective in controlling PMS symptoms for long‐term use (<a href="./references#CD010503-bbs2-0019" title="GreenLJ , O’BrienPMS , PanayN , Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol2017;124:e73‐e105. ">Green 2017</a>). Though oestrogen appears to be an effective agent for treating PMS, its use may be limited in individual women by the need for progestogen in women with a uterus and because of the subsequent progestogen PMS‐like side effects. As oestrogen‐only treatment has been found to be associated with endometrial hyperplasia/cancer, progestogen therapy is recommended for endometrial protection. The use of local progestogen (levonorgestrel‐releasing intrauterine system) may reduce the occurrence of PMS‐like side effects but there are no fully published randomized controlled trials (RCTs). We specifically exclude studies on oral contraceptives (OCs), especially those containing drospirenone, as this has been considered in an earlier Cochrane Review (<a href="./references#CD010503-bbs2-0026" title="LopezLL , KapteinAA , HelmerhorstFM . Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD006586.pub4] ">Lopez 2012</a>). </p> </section> <section id="CD010503-sec-0041"> <h3 class="title" id="CD010503-sec-0041">Why it is important to do this review</h3> <p>Whilst there are several published trials of oestrogen treatment of PMS and it is widely used, there is no existing systematic review evaluating the therapeutic effectiveness of non‐contraceptive oestrogen‐containing preparations in the management of PMS. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010503-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010503-sec-0042"></div> <p>To determine the effectiveness and safety of non‐contraceptive oestrogen‐containing preparations in the management of PMS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010503-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010503-sec-0043"></div> <section id="CD010503-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010503-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials, either published or unpublished. We excluded non‐randomized studies (for example studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias. Cross‐over trials were eligible if feasible data from both phases could be included in meta‐analyses. </p> </section> <section id="CD010503-sec-0046"> <h4 class="title">Types of participants</h4> <section id="CD010503-sec-0047"> <h5 class="title">Inclusion</h5> <p>Women in the studies had to be of reproductive age. Diagnosis of PMS had to be confirmed by prospective recording of symptoms for at least two menstrual cycles. Diagnosis through established criteria as set out in the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM‐III, DSM‐IV or DSM‐V) was not specified so as not to exclude older studies. </p> </section> <section id="CD010503-sec-0048"> <h5 class="title">Exclusion</h5> <p>We excluded studies if participants had only a self‐diagnosis of PMS, were on other medication which resulted in ovulation suppression, had a primary psychiatric diagnosis other than premenstrual dysphoric disorder, or were taking any other hormone therapy (i.e. other than oestrogen and progestogens). Studies with participants already receiving psychotropic medication (e.g. selective serotonin re‐uptake inhibitors) were not excluded. </p> </section> </section> <section id="CD010503-sec-0049"> <h4 class="title">Types of interventions</h4> <p>We included studies which compared the effects of non‐contraceptive oestrogen‐containing preparations (with or without progestogen) versus placebo or alternative treatment; and studies which compared different dosages of oestrogen. </p> <p>We included all routes of administration (e.g. oral, vaginal, transdermal patch, cream, gels, intrauterine route) or dosing regimen, provided the duration was longer than one menstrual cycle. </p> <p>All combined oral contraceptive preparations (oestrogen/progestogen) were excluded, as were all studies of progestogen alone. </p> </section> <section id="CD010503-sec-0050"> <h4 class="title">Types of outcome measures</h4> <p>The following outcomes were considered in this review.</p> <section id="CD010503-sec-0051"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010503-list-0001"> <li> <p>Effectiveness (global symptom scores assessed using a validated prospective screening tool or by pre‐defined medical diagnostic criteria). </p> </li> <li> <p>Adverse events (specific adverse effects including withdrawals for adverse effects and abnormal uterine bleeding). </p> </li> </ol> </p> </section> <section id="CD010503-sec-0052"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010503-list-0002"> <li> <p>Specific symptoms of PMS: psychological, physical and functional symptoms.</p> </li> <li> <p>Quality of life measures.</p> </li> <li> <p>Participant satisfaction.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010503-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <p>We looked up all published and unpublished randomized controlled trials (RCTs) of non‐contraceptive oestrogens versus placebo, non‐contraceptive oestrogens versus alternative treatments and non‐contraceptive oestrogens at different dosages. All searches were conducted without language restriction and in consultation with the Cochrane Gynaecology and Fertility Group Information Specialist. We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress). </p> <section id="CD010503-sec-0054"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched the Cochrane Gynaecology and Fertility (CGF) Specialised Register of Controlled Trials, Cochrane Central Register of Studies (CRSO), MEDLINE, Embase, PsycINFO and CINAHL on 14 March 2016. The complete search strategies for the database searches are provided in <a href="./appendices#CD010503-sec-0144">Appendix 1</a>, <a href="./appendices#CD010503-sec-0145">Appendix 2</a>, <a href="./appendices#CD010503-sec-0146">Appendix 3</a>, <a href="./appendices#CD010503-sec-0147">Appendix 4</a>, <a href="./appendices#CD010503-sec-0148">Appendix 5</a> and <a href="./appendices#CD010503-sec-0149">Appendix 6</a>. There was no restriction on language. </p> <p>We searched for ongoing and unpublished studies in trial registers, such as ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov/</a>), metaRegister of Controlled trials (mRCT) (<a href="http://www.controlled-trials.com/mrct/" target="_blank">www.controlled‐trials.com/mrct/</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). </p> <p>We searched for relevant conference abstracts on the ISI Web of Knowledge.</p> </section> <section id="CD010503-sec-0055"> <h4 class="title">Searching other resources</h4> <section id="CD010503-sec-0056"> <h5 class="title">Handsearching of conference proceedings</h5> <p>Proceedings from the following main conferences were handsearched.</p> <p> <ul id="CD010503-list-0003"> <li> <p>International Federation of Fertility Societies.</p> </li> <li> <p>American Society for Reproductive Medicine.</p> </li> <li> <p>British Fertility Society.</p> </li> <li> <p>European Society for Human Reproduction and Embryology.</p> </li> </ul> </p> </section> <section id="CD010503-sec-0057"> <h5 class="title">Researchers and organizations</h5> <p> <ul id="CD010503-list-0004"> <li> <p>We contacted individual researchers working in the field to identify unpublished and ongoing trials. </p> </li> <li> <p>We also contacted the UK‐based National Association for Premenstrual Syndrome (NAPS) for relevant articles. </p> </li> <li> <p>We contacted the following drug and pharmaceutical companies manufacturing oestrogen to request other published or unpublished trials: Organon, Bayer Health Care, Janssen, Abbott, Pfizer, ReSource Medical, Meda, Norvartis, Orion, Teva UK and Marlborough Pharmaceuticals. </p> </li> </ul> </p> </section> <section id="CD010503-sec-0058"> <h5 class="title">Reference lists</h5> <p>We also checked the reference lists of all studies identified by the above methods and examined any systematic reviews or meta‐analyses found. </p> </section> </section> </section> <section id="CD010503-sec-0059"> <h3 class="title" id="CD010503-sec-0059">Data collection and analysis</h3> <p>Data collection and analysis were conducted in accordance with guidelines set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD010503-sec-0060"> <h4 class="title">Selection of studies</h4> <p>Two authors (BN and OU) independently applied inclusion criteria to all identified trials. We used the titles and abstracts of the identified citations to exclude trials that clearly did not meet the inclusion criteria (<a href="#CD010503-fig-0001">Figure 1</a>). If either author judged that the trial might be eligible for inclusion, we obtained the full paper. We independently screened the full articles of selected trials and resolved any disagreements with a third author (PMSO). We gave reasons for excluding potentially relevant trials in <a href="./references#CD010503-sec-0159" title="">Characteristics of excluded studies</a>. We attempted to contact the authors for clarification. </p> <div class="figure" id="CD010503-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010503-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The selection process was illustrated in a flow diagram according to the PRISMA statement (<a href="#CD010503-fig-0001">Figure 1</a>) (<a href="./references#CD010503-bbs2-0028" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>). </p> </section> <section id="CD010503-sec-0061"> <h4 class="title">Data extraction and management</h4> <p>Two authors (BN and JHK) independently extracted the data using a pre‐designed data collection form. For each of the studies, we extracted the following data: citation, study design, methodological criteria, inclusion and exclusion criteria, comparison group intervention, participant characteristics, trial setting, elements of intervention, all relevant outcomes measures, and results. Where reports were uncertain or included only summary measures, authors were contacted for clarification. </p> <p>We also took note of any data that were consistently underreported, and highlighted this deficit along with future research needs. We checked whether authors had conducted an intention‐to‐treat (ITT) analysis (all randomized participants should be analyzed in the groups to which they were originally randomized) or one of its modifications (modified intention‐to‐treat or mITT; <a href="./references#CD010503-bbs2-0011" title="AbrahaI , MontedoriA . Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ2010;340:C2697. ">Abraha 2010</a>). We calculated the percentage lost to follow‐up and reported this information. For dichotomous outcome measures, we recorded the number of participants experiencing the event and the number analyzed in each group. For continuous outcome measures, we extracted the mean change from baseline, the standard deviation of the mean change, and the number of women for each treatment group at each assessment. </p> <p>Where changes from baseline were not reported, the mean, standard deviation, and the number of participants for each intervention group at each point in time were extracted. If the data had been reported using geometric means, we recorded this information and extracted a standard deviation on a log scale. </p> <p>In studies with a cross‐over design, data were taken from both periods. We contacted authors for clarification and missing or insufficient data. </p> </section> <section id="CD010503-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BN and JHK) independently assessed the included studies for risk of bias using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>This assesses (<a href="./appendices#CD010503-sec-0150">Appendix 7</a>): </p> <p> <ul id="CD010503-list-0005"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, providers and outcome assessors;</p> </li> <li> <p>completeness of outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other potential sources of bias, such as inappropriate administration of the intervention or the risk of carry‐over effects in cross‐over trials. </p> </li> </ul> </p> <p>We presented results in both a risk of bias graph and a risk of bias summary. We interpreted the results of meta‐analyses in the light of the findings with respect to risk of bias. We conducted a sensitivity analysis based on risk of bias. We resolved any disagreements by consensus or by discussion with a third author. </p> </section> <section id="CD010503-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (e.g. adverse events), we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel risk ratios (RRs). For continuous data (e.g. mood score), if all studies reported exactly the same outcomes on the same scale we calculated mean differences (MDs) between treatment groups. If similar outcomes were reported on different scales (e.g. Moos Menstrual Distress Questionnaire (MDQ) and Premenstrual Distress Questionnaire (PDQ)) for premenstrual symptoms we calculated the standardized mean difference (SMD). We reversed the direction of effect of individual studies, if required, to ensure consistency across trials. We presented 95% confidence intervals (CIs) for all outcomes. Where data to calculate RRs or MDs were not available, we utilized the most detailed numerical data available that facilitated similar analyses of included studies (e.g. test statistics, P values). If a separate mean for each treatment arm could not be retrieved but the difference and within‐group standard deviation were available, we used the generic inverse‐variance method in the analyses using Hedges' g to calculate the standardized mean difference (SMD) (<a href="./references#CD010503-bbs2-0014" title="DeeksJJ , Higgins JPT on behalf of the Statistical Methods Group of The Cochrane Collaboration. Statistical algorithms in Review Manager; August 2010. tech.cochrane.org/revman/documentation/statistical‐methods‐in‐revman‐5.pdf (accessed 11 January 2017). ">Deeks 2010</a>). We compared the magnitude and direction of effect reported by studies with how they are presented in the review, taking account of legitimate differences. </p> <p>SMDs were interpreted using the following rule of thumb: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). A moderate effect (i.e. SMD = 0.5) can be interpreted as the smallest change that an individual person can perceive (<a href="./references#CD010503-bbs2-0029" title="NormanGR , SloanJA , WyrwichKW . Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Medical Care2003;41(3):582‐92. ">Norman 2003</a>). </p> </section> <section id="CD010503-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was per woman. We planned that if the woman was not the unit of randomization, such as is the case in cluster randomized trial (general practitioners, for example, might be the unit of randomization), adjustments for clustering would be made following the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>In trials with a cross‐over design data were taken from both periods and analyzed as if they were from a parallel trial (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a> section 16.4.5). This means that each trial participant contributed to both trial arms unless they dropped out during the second part of the trial, and therefore each cross‐over trial participant was effectively counted as two women. This approach gives rise to a unit of analysis error, but is conservative in that studies are under‐weighted rather than over‐weighted. </p> </section> <section id="CD010503-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>The data were analyzed on an intention‐to‐treat basis as far as possible and attempts were made to obtain missing data from the original trialists. Where these were unobtainable, we analyzed only the available data. </p> </section> <section id="CD010503-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>The authors considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a meaningful summary. Statistical heterogeneity was assessed by measurement of the I² statistic. An I² greater than 50% was taken to indicate substantial heterogeneity (<a href="./references#CD010503-bbs2-0021" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). If substantial heterogeneity was detected, possible explanations were explored in sensitivity analyses </p> <p>A rough guide to interpretation of I² values is as follows (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p> <ul id="CD010503-list-0006"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD010503-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD010503-sec-0068"> <h4 class="title">Data synthesis</h4> <p>All eligible studies were analyzed in Cochrane's statistical software, <a href="./references#CD010503-bbs2-0034" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. Of the two authors who extracted the data, the first author entered all data into Review Manager 5 in collaboration with a third author, and the second rechecked all entries. Authors resolved disagreements by discussion. They provided a narrative synthesis for all results, along with a statistical meta‐analysis if possible. An increase in the probability of a particular outcome, which may be beneficial (e.g. improvement in global symptoms' scores) or detrimental (e.g. adverse effects), was displayed graphically in the meta‐analyses to the right of the centre‐line and a decrease in the odds of an outcome to the left of the centre‐line. </p> <p>If the studies were sufficiently similar, we combined the data using a fixed‐effect model in the following comparisons. </p> <p> <ol id="CD010503-list-0007"> <li> <p>Oestrogen versus placebo.</p> </li> <li> <p>Oestrogen in combination with progestogen (sequential or continuous) versus placebo.</p> </li> <li> <p>Dose comparisons of oestrogen, with or without progestogen.</p> </li> </ol> </p> </section> <section id="CD010503-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we conducted a subgroup analysis to determine the separate evidence within the following subgroups. </p> <p> <ul id="CD010503-list-0008"> <li> <p>Subgroups by route of administration of oestrogens.</p> </li> <li> <p>Subgroups by mode of administration (continuous versus phasic).</p> </li> <li> <p>Subgroups by route of administration of co‐administered progestogens required for protection of endometrium (not for therapeutic effects as indeed they may re‐introduce PMS‐like symptoms). </p> </li> </ul> </p> <p>If we detected substantial heterogeneity, we planned to explore possible explanations in sensitivity analyses. We planned to take any statistical heterogeneity into account when interpreting the results, especially if there is any variation in the direction of effect. </p> </section> <section id="CD010503-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if: </p> <p> <ol id="CD010503-list-0009"> <li> <p>eligibility were restricted to studies without high risk of bias;</p> </li> <li> <p>a random‐effects model had been adopted;</p> </li> <li> <p>the summary effect measure was odds ratio (OR) rather than RR.</p> </li> </ol> </p> <section id="CD010503-sec-0071"> <h5 class="title">Summary of findings table</h5> <p>A 'Summary of findings' table was generated using GRADEPRO software (<a href="./references#CD010503-bbs2-0018" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 4 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>) and Cochrane methods (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) to evaluate the overall quality of the body of evidence for our main comparisons (oestrogen vs placebo and oestrogen plus progestogen versus placebo) for our primary review outcomes (effectiveness and adverse events). Two review authors independently assessed the studies, using GRADE working group criteria (i.e. study limitations (risk of bias), consistency of effect, imprecision, indirectness and publication bias) (<a href="./references#CD010503-bbs2-0013" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:7454. ">Atkins 2004</a>). Judgements about the quality of the evidence (high, moderate, low or very low) were justified, documented, and incorporated into reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010503-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010503-sec-0072"></div> <section id="CD010503-sec-0073"> <h3 class="title">Description of studies</h3> <section id="CD010503-sec-0074"> <h4 class="title">Results of the search</h4> <p>We prepared a PRISMA flowchart to describe how we processed the references identified through the search results (see <a href="#CD010503-fig-0001">Figure 1</a>) (<a href="./references#CD010503-bbs2-0028" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>). The literature searches yielded 524 titles of potentially relevant articles. After scanning titles and abstracts, we identified a total of 10 potentially relevant articles and two authors independently assessed full‐text copies against the inclusion criteria. We scanned the reference lists of these studies for further studies, but none were found. Eventually, we excluded five studies with reasons and five studies met the inclusion criteria. </p> <p>See <a href="./references#CD010503-sec-0158" title="">Characteristics of included studies</a> and <a href="./references#CD010503-sec-0159" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD010503-sec-0075"> <h4 class="title">Included studies</h4> <section id="CD010503-sec-0076"> <h5 class="title">Study design and setting</h5> <p>Five trials were eligible for inclusion. All trials had a randomized controlled design (see <a href="./references#CD010503-sec-0158" title="">Characteristics of included studies</a> for detailed information about the individual trials). Three trials used a cross‐over design (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>); and two a parallel design (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>). Four of the trials came from a single unit at King's College Hospital under the direction of Prof J Studd, Consultant Obstetrician and Gynaecologist (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). </p> <p>All but one study reviewed were conducted in the UK. The exception was conducted in Canada (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>). </p> </section> <section id="CD010503-sec-0077"> <h5 class="title">Participants</h5> <p>This review was based on data from 258 participants. The mean number of participants per trial was 65 (range 11 to 112); (see <a href="./references#CD010503-sec-0158" title="">Characteristics of included studies</a> for breakdown per study). </p> <p>Exclusion criteria varied but most of the studies excluded women with the following characteristics. </p> <p> <ul id="CD010503-list-0010"> <li> <p>Women with only a self‐diagnosis of PMS.</p> </li> <li> <p>Women who were on other medication which resulted in ovulation suppression.</p> </li> <li> <p>Women with a primary psychiatric diagnosis (other than premenstrual dysphoric disorder).</p> </li> <li> <p>Women who were taking any other hormone therapy (i.e. other than oestrogen and progestogens) though women already receiving psychotropic medication (e.g. selective serotonin re‐uptake inhibitors) were not excluded. </p> </li> </ul> </p> </section> <section id="CD010503-sec-0078"> <h5 class="title">Interventions</h5> <p><a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> investigated a subcutaneous oestrogen implant with 5 mg oral norethisterone for 7 days per cycle. versus placebo with placebo implant for 7 days per cycle. </p> <p><a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> investigated oestrogen patches with 5 mg oral norethisterone, day 19 to 26, versus placebo patches plus 5 mg oral norethisterone, day 19 to 26. </p> <p><a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> investigated 100 µg oestradiol patches with 1 mg oral norethisterone at 17 to 28 days versus identical placebo patches and tablets. </p> <p><a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> compared different doses of oestrogen patches (100 µg versus 200 µg). In each group half of the women were allocated to take dydrogesterone 10 mg daily from day 17 to 26 of the cycle and half to take medroxyprogesterone acetate 5 mg daily from day 17 to 26. </p> <p><a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a> investigated oral oestrogen versus placebo. </p> </section> <section id="CD010503-sec-0079"> <h5 class="title">Outcomes</h5> <p>All studies reported global symptom scores.</p> <p>Four studies reported adverse events (specific adverse effects including withdrawals as a result of adverse effects and abnormal uterine bleeding). </p> <section id="CD010503-sec-0080"> <h6 class="title">Primary outcome measures</h6> <p>The primary outcome measures of effectiveness used in the studies were the Moos Menstrual Distress Questionnaire (MDQ) (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>), the Premenstrual Distress Questionnaire (PDQ; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>), and a 28‐question mental and physical symptoms daily ratings scale (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>). The MDQ and PDQ are validated scales, in contrast to the 28‐question daily ratings scale. For all three scales, a higher score indicated more — or more severe — symptoms, in other words a worse outcome. The studies using MDQ and PDQ could be pooled by using standardized mean differences. One study did not provide an SD but did include the 10th and 90th centile of changes in score, which were therefore used to calculate an SD (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>). Another study (<a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>) did not provide enough information to determine the SD, and we therefore used the pooled SD from another included study (<a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>). Although <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> was a cross‐over trial, the statistical analysis in the paper was performed as for a parallel trial. Too few data were presented in the paper to perform a re‐analysis, and therefore we reported the data in its original parallel trial form. Likewise, the modified ITT analysis reported in the statistical report accompanying <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>, which was based on all women who provided a follow‐up score, performed the analysis as for a parallel trial. The primary outcome measure of adverse effect was the frequency of adverse effects and abnormal laboratory tests mentioned in the publications. All studies had data in a form that allowed a pooled analysis. </p> </section> <section id="CD010503-sec-0081"> <h6 class="title">Secondary outcome measures</h6> <p>Secondary outcome measures of effectiveness used in the study were psychological and physical symptoms as provided by the MDQ, PDQ and the 28‐question ratings scale subscores. For all these scales, a higher score indicated more or more severe symptoms (or both), in other words a worse outcome. The outcomes for these two symptoms were pooled by using standardized mean differences, again using the pooled SD from one included study — <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> — to substitute for the missing information in <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>. Further secondary outcomes were a Visual Analog Scale (VAS) of general unwellness or well‐being (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>), the GHQ‐60 general health questionnaire (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>), and participant satisfaction (<a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>). For the VAS of feeling unwell and the GHQ‐60, a higher score indicated a worse outcome, whereas for the VAS of feeling well a higher score indicated a better outcome. </p> </section> <section id="CD010503-sec-0082"> <h6 class="title">Sources of support</h6> <p><a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> was supported by industry; <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> by a research charity; and three studies provided no information on support (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). </p> </section> </section> </section> <section id="CD010503-sec-0083"> <h4 class="title">Excluded studies</h4> <p>Five studies were excluded from this review. One randomized trial was excluded because it did not compare oestrogen treatment to either placebo or comparator control (<a href="./references#CD010503-bbs2-0008" title="DomoneyC , PanayN , HawkinsA , StuddJ . Treatment of premenstrual syndrome with transdermal oestrogen. International Journal of Gynaecology &amp; Obstetrics2003;83(suppl 3):37‐8. ">Domoney 2003</a>). Three randomized trials were excluded because they were restricted to specific aspects of PMS instead of global symptoms (<a href="./references#CD010503-bbs2-0006" title="deLignièresB , VincensM , Mauvais‐JarvisP , MasJL , TouboulPJ , BousserMG . Prevention of menstrual migraine by percutaneous oestradiol. British Medical Journal (Research Edition)1986;293(6561):1540. ">de Lignières 1986</a>; <a href="./references#CD010503-bbs2-0007" title="DennersteinL , MorseC , BurrowsG , OatsJ , BrownJ , SmithM . Menstrual migraine: a double‐blind trial of percutaneous estradiol. Gynecological Endocrinology1988;2(2):113‐20. ">Dennerstein 1988</a>; <a href="./references#CD010503-bbs2-0009" title="EnsomMH , ChongG , ZhouD , BeaudinB , ShalanskyS , BaiTR . Estradiol in premenstrual asthma: a double‐blind, randomized, placebo‐controlled, crossover study. Pharmacotherapy2003;23(5):561‐71. ">Ensom 2003</a>). One randomized trial was excluded because it made use of oestrogen as part of a contraceptive (<a href="./references#CD010503-bbs2-0010" title="HalbreichU , FreemanEW , RapkinAJ , CohenLS , GrubbGS , BergeronR , et al. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception2012;85(1):19‐27. ">Halbreich 2012</a>). </p> </section> </section> <section id="CD010503-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010503-fig-0002">Figure 2</a> and <a href="#CD010503-fig-0003">Figure 3</a>, and <a href="./references#CD010503-sec-0158" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD010503-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010503-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010503-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010503-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010503-sec-0085"> <h4 class="title">Allocation</h4> <section id="CD010503-sec-0086"> <h5 class="title">Random sequence generation</h5> <p><a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> and <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> were judged to have a low risk and <a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>, <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> to have an unclear risk of bias, the latter because details of the randomisation method were not supplied. </p> </section> <section id="CD010503-sec-0087"> <h5 class="title">Allocation concealment</h5> <p><a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>, <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> and <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> were judged to have a low risk and <a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> to have an unclear risk of this bias. </p> </section> </section> <section id="CD010503-sec-0088"> <h4 class="title">Blinding</h4> <p><b>Performance bias</b> </p> <p><a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> were judged to have a low risk and <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> to have a high risk of this bias. </p> <p><b>Detection bias</b> </p> <p><a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> were judged to have a low risk and <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> to have a high risk of this bias. </p> </section> <section id="CD010503-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>Three of the five trials had high rates of dropout or loss to follow up, ranging from 20% to 29% (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>); these were rated at high risk of attrition bias. <a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> were rated at low risk. </p> <p>A potential risk of bias in cross‐over trials is dropout after the first phase, whereby the participant does not start the second treatment. In <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>, four of the five withdrawals occurred in the first phase and therefore did not bias the results in the two arms differentially. One woman in the active‐to‐placebo group withdrew at three months because she did not want to change treatment because of dramatic improvement. In <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>, all withdrawals but one occurred within the first phase of the trial, Therefore no reasons were found to suspect a systematic difference between the two trial phases due to dropout after the first phase but before the second phase. </p> </section> <section id="CD010503-sec-0090"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> (all five studies) were judged to have a low risk of bias. </p> </section> <section id="CD010503-sec-0091"> <h4 class="title">Other potential sources of bias</h4> <p>Three of the studies were cross‐over trials (<a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>; <a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>). The International Society for Premenstrual Disorders (ISPMD) Montreal Consensus agreed that randomized trials of premenstrual disorders should ideally have a parallel design (<a href="./references#CD010503-bbs2-0023" title="O'BrienPMS , BäckströmT , BrownC , DennersteinL , EndicottJ , EppersonCN , et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Archives of Women's Mental Health2011;14(1):13. ">ISPMD 2011</a>), suggesting these trials were not ideal. The main risks of cross‐over trials are the potential for carry‐over effects from one period to the next, and an increased risk of attrition. The issue of carry‐over effects was not addressed in the three trial reports. The month‐by‐month graphical data of the active‐to‐placebo group in <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> strongly suggest that the effect of the active treatment has disappeared in the month after the transition from active to placebo, but we rated the risk of bias from carry‐over effects unclear given that only graphical data from a single trial supports it. </p> </section> </section> <section id="CD010503-sec-0092"> <h3 class="title" id="CD010503-sec-0092">Effects of interventions</h3> <p>See: <a href="./full#CD010503-tbl-0001"><b>Summary of findings for the main comparison</b> Oestrogen in combination with progestogen (sequential or continuous) compared to placebo for controlling symptoms of premenstrual syndrome</a>; <a href="./full#CD010503-tbl-0002"><b>Summary of findings 2</b> Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</a>; <a href="./full#CD010503-tbl-0003"><b>Summary of findings 3</b> Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</a> </p> <section id="CD010503-sec-0093"> <h4 class="title">1. Oestrogen versus placebo</h4> <p>One study reported this comparison (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>). Luteal‐phase oestrogen was compared with placebo. As the study used non‐validated scales to measure effectiveness and specific (psychological and physical) symptoms of PMS, findings are reported in narrative rather than in forest plots. The quality of the evidence for this comparison was rated as very low (<a href="./full#CD010503-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD010503-sec-0094"> <h5 class="title">Primary outcomes</h5> <section id="CD010503-sec-0095"> <h6 class="title">1.1 Effectiveness</h6> <p>The study authors reported that luteal‐phase oestrogen had a large negative effect on global (mental and physical) symptoms compared to placebo (P &lt; 0.01). </p> </section> <section id="CD010503-sec-0096"> <h6 class="title">1.2 Adverse events</h6> <p>None of the 11 women withdrew from the study. The study authors reported that "no significant adverse events were encountered" but did not specify what the nature of a "significant adverse event" would be. </p> </section> </section> <section id="CD010503-sec-0097"> <h5 class="title">Secondary outcomes</h5> <section id="CD010503-sec-0098"> <h6 class="title">1.3 Specific symptoms of PMS: psychological, physical and functional symptoms</h6> <section id="CD010503-sec-0099"> <p><b>1.3.1 Psychological symptoms</b></p> <p>The study authors reported that luteal‐phase oestrogen was significantly less effective than placebo in relieving the severity of mental symptoms of PMS (P &lt; 0.02). </p> </section> <section id="CD010503-sec-0100"> <p><b>1.3.2 Physical symptoms</b></p> <p>The study authors reported that luteal‐phase oestrogen was significantly less effective than placebo in relieving the severity of physical symptoms of PMS (P &lt; 0.02). </p> </section> </section> <section id="CD010503-sec-0101"> <h6 class="title">1.4 Quality of life</h6> <p>This outcome was not reported.</p> </section> <section id="CD010503-sec-0102"> <h6 class="title">1.5 Patient satisfaction</h6> <p>This outcome was not reported.</p> </section> </section> </section> <section id="CD010503-sec-0103"> <h4 class="title">2. Oestrogen in combination with progestogen (sequential or continuous) versus placebo.</h4> <p>Three studies reported this comparison. They compared continuous oestrogen (as an implant or patch) with sequential placebo versus placebo. One of the studies administered progestogen in both arms (<a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>)<i>.</i> We have included this study in this comparison and conducted a post hoc sensitivity analysis to see whether inclusion of this study influenced the results. The quality of the evidence for this comparison was rated as very low (<a href="./full#CD010503-tbl-0001">summary of findings Table for the main comparison</a>) </p> <section id="CD010503-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD010503-sec-0105"> <h6 class="title">2.1 Effectiveness</h6> <p>Continuous oestrogen (implants and patches) had a moderately positive effect on global symptom scores compared to placebo (SMD −0.27, 95% CI −0.47 to −0.07, P = 0.008, 3 RCTs, 158 women, effective sample size 267 women considering cross‐over trials, I² = 63%, very low quality evidence; <a href="./references#CD010503-fig-0006" title="">Analysis 1.1</a>; <a href="#CD010503-fig-0004">Figure 4</a>). The statistical heterogeneity between the three trials appeared to be mainly attributable to <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>, in which a low‐dose patch (100 µg) was used. When <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> was excluded from the analysis, findings were no longer statistically significant (SMD −0.19, 95% CI −0.40 to 0.03). </p> <div class="figure" id="CD010503-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.1 Symptom scores." data-id="CD010503-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.1 Symptom scores. </p> </div> </div> </div> </section> <section id="CD010503-sec-0106"> <h6 class="title">2.2 Adverse events</h6> <p>All three studies reported withdrawals due to adverse events. Confidence intervals were very wide and there were too few events (none in one of the studies), to establish whether there was a difference between the groups (RR 0.64, 95% CI 0.26 to 1.58, P = 0.33, 3 RCTs, 196 women, effective sample size 284 women considering cross‐over trials, I² = 0%, low‐quality evidence; <a href="./references#CD010503-fig-0007" title="">Analysis 1.2</a>; <a href="#CD010503-fig-0005">Figure 5</a>). Excluding <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> from the analysis did not influence the findings. </p> <div class="figure" id="CD010503-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events." data-id="CD010503-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events. </p> </div> </div> </div> <p>The two studies comparing oestrogen versus placebo also reported specific adverse events (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-fig-0008" title="">Analysis 1.3</a>). There were too few events reported to determine whether there was a difference between the groups. </p> <p>Findings for specific events were as follows.</p> <p> <ul id="CD010503-list-0011"> <li> <p>Bleeding problems (RR 0.53, 95% CI 0.10 to 2.70, P = 0.45, 1 RCT, 68 women, very low quality evidence). </p> </li> <li> <p>Breast tenderness (RR 1.64, 95% CI 0.87 to 3.11, P = 0.13, 2 RCTs, 206 women, I² = 69%, very low quality evidence). </p> </li> <li> <p>Headache (RR 0.91, 95% CI 0.53 to 1.57, P = 0.74, 2 RCTs, 206 women, I² = 0%, very low quality evidence). </p> </li> <li> <p>Nausea (RR 1.22, 95% CI 0.55 to 2.71, P = 0.62, 2 RCTs, 206 women, I² = 0%, very low quality evidence). </p> </li> <li> <p>Weight gain (RR 11.65, 95% CI 0.67 to 202.74, P = 0.09, 1 RCT, 68 women, very low quality evidence). </p> </li> <li> <p>Dysmenorrhoea (RR 1.55, 95% CI 0.78 to 3.05, P = 0.21, 1 RCT, 138 women, very low quality evidence). </p> </li> <li> <p>Skin irritation (RR 1.00, 95% CI 0.39 to 2.58, P = 1.0, 1 RCT, 40 women, very low quality evidence). </p> </li> <li> <p>Skin reactions (RR 0.56, 95% CI 0.19 to 1.59, P = 0.27, 2 RCTs, 178 women, I² = 0%, very low quality evidence). </p> </li> <li> <p>Skin pigmentation (RR 11.00, 95% CI 0.65 to 186.62, P = 0.10, 1 RCT, 40 women, very low quality evidence). </p> </li> </ul> </p> </section> </section> <section id="CD010503-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD010503-sec-0108"> <h6 class="title">2.3 Specific symptoms of PMS: psychological, physical and functional symptoms</h6> <section id="CD010503-sec-0109"> <p><b>2.3.1 Psychological symptoms</b></p> <p>Two placebo‐controlled RCTs of continuous oestrogen plus progestogen (implants or patches) provided data to determine effects on psychological symptoms (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). Treatment with implants or patches was associated with a reduction in psychological symptoms compared to treatment with placebo (SMD −0.79, 95% Cl −1.17 to −0.40, P &lt; 0.00007, 2 RCTs, 88 women, effective sample size 119 women considering the cross‐over trial, I² = 78%, very low quality evidence). Findings were imprecise and compatible with an effect size ranging from small to large (<a href="./references#CD010503-fig-0009" title="">Analysis 1.4</a>). </p> <p>However, when <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> was excluded from the analysis, findings were no longer statistically significant (SMD −0.33, 95% CI −0.90 to 0.24). </p> </section> <section id="CD010503-sec-0110"> <p><b>2.3.2 Physical symptoms</b></p> <p>Two placebo‐controlled trials of continuous oestrogen plus progestogen (implants or patches) provided data to determine effects on physical symptoms (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). Physical symptoms were lower in the oestrogen group (SMD −0.60, 95% Cl −0.98 to −0.22, P = 0.0019, 2 RCTs, 88 women, effective sample size 119 women considering the crossover trial, I² = 52%, very low quality evidence). Findings were imprecise and compatible with an effect size ranging from small to large (<a href="./references#CD010503-fig-0010" title="">Analysis 1.5</a>). </p> <p>However, when <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> was excluded from the analysis, findings were no longer statistically significant (SMD −0.29, 95% CI −0.86 to 0.28). </p> </section> </section> <section id="CD010503-sec-0111"> <h6 class="title">2.4 Quality of life</h6> <p>One placebo‐controlled trial of continuous oestrogen (implants) reported on general quality of life (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>). There was no conclusive evidence of difference in a VAS for feeling unwell (MD −10.90, 95% CI −22.60 to 0.80, P = 0.07, 1 RCT, 40 women, effective sample size 68 women considering this was a cross‐over trial, low‐quality evidence) and a general health questionnaire (MD −3.30, 95% CI −9.98 to 3.38, P = 0.33, 1 RCT, 40/68 women, very low quality evidence) (<a href="./references#CD010503-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD010503-sec-0112"> <h6 class="title">2.5 Patient satisfaction</h6> <p>This outcome was not reported in the included studies.</p> </section> </section> </section> <section id="CD010503-sec-0113"> <h4 class="title">3 Dose comparisons of oestrogen, 100 µg versus 200 µg, with or without progestogen</h4> <p>One study compared different doses of oestrogen patches (100 µg versus 200 µg) (<a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>). In each group half of the women were allocated to take dydrogesterone 10 mg daily from day 17 to 26 of the cycle and half to take medroxyprogesterone acetate 5 mg daily from day 17. The quality of the evidence for this comparison was rated as very low (<a href="./full#CD010503-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD010503-sec-0114"> <h5 class="title">Primary outcomes</h5> <section id="CD010503-sec-0115"> <h6 class="title">3.1 Effectiveness</h6> <p>The evidence was too imprecise to determine whether dosage had an effect on global symptoms (MD −1.55 on a scale of 0 to 30, 95% CI −8.88 to 5.78, P = 0.68, 1 RCT, 98 women, very low quality evidence) (<a href="./references#CD010503-fig-0012" title="">Analysis 2.1</a>). </p> </section> <section id="CD010503-sec-0116"> <h6 class="title">3.2 Adverse events</h6> <p>The evidence was too imprecise to determine whether there was a difference between the two patch dosages in withdrawal rates for adverse events (RR 0.70, 95% CI 0.34 to 1.46, P = 0.34, 1 RCT, 107 women, very low quality evidence) (<a href="./references#CD010503-fig-0013" title="">Analysis 2.2</a>). </p> <p>The evidence suggested that there might be a lower overall risk of adverse events in the 100 µg group (RR 0.51, 95% Cl 0.26 to 0.99, P = 0.05, 1 RCT, 107 women, very low quality evidence) (<a href="./references#CD010503-fig-0013" title="">Analysis 2.2</a>). The data did not allow extraction of individual adverse event risks by dosage. </p> </section> </section> <section id="CD010503-sec-0117"> <h5 class="title">Secondary outcomes</h5> <section id="CD010503-sec-0118"> <h6 class="title">3.3 Specific symptoms of PMS: psychological, physical and functional symptoms</h6> <section id="CD010503-sec-0119"> <p><b>3.3.1 Psychological symptoms</b></p> <p>The evidence was too imprecise to determine whether there a difference between the two dosage groups (MD −0.28, 95% CI −1.17 to 0.61, P = 0.54, 1 RCT, 98 women, very low quality evidence) (<a href="./references#CD010503-fig-0014" title="">Analysis 2.3</a>). </p> </section> <section id="CD010503-sec-0120"> <p><b>3.3.2 Physical symptoms</b></p> <p>The evidence was too imprecise to determine whether there a difference between the two dosage groups (MD −0.33, 95% CI −1.17 to 0.51, P = 0.44, 1 RCT, 98 women, very low quality evidence) (<a href="./references#CD010503-fig-0014" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD010503-sec-0121"> <h6 class="title">3.4 Quality of life</h6> <p>This study used a VAS (scale 0 to 100) for feeling well to report on general quality of life. The evidence was too imprecise to determine whether there a difference between the two dosage groups (MD 1.70, 95% CI −19.43 to 22.83, P = 0.87, 1 RCT, 98 women, very low quality evidence) (<a href="./references#CD010503-fig-0015" title="">Analysis 2.4</a>). </p> </section> <section id="CD010503-sec-0122"> <h6 class="title">3.5 Patient satisfaction</h6> <p>The evidence was too imprecise to determine whether there a difference in satisfaction rates between the two dosage groups (RR 1.19, 95% CI 0.85 to 1.68, P = 0.32, 1 RCT, 107 women, very low quality evidence) (<a href="./references#CD010503-fig-0016" title="">Analysis 2.5</a>). </p> </section> </section> </section> <section id="CD010503-sec-0123"> <h4 class="title">Other analyses</h4> <section id="CD010503-sec-0124"> <h5 class="title">Subgroup analyses</h5> <p>Our planned subgroup analyses were not possible due to lack of data.</p> </section> <section id="CD010503-sec-0125"> <h5 class="title">Sensitivity analyses</h5> <section id="CD010503-sec-0126"> <h6 class="title">Restricting eligibility to studies without high risk of bias</h6> <p>All five included studies had at least one item with a high risk of bias or multiple items with an unknown risk. Restricting eligibility to studies without an item with high risk of bias was therefore impossible. </p> <p>The three RCTs comprising the analysis of implants or patches had substantial heterogeneity (I² = 54%), mainly due to one RCT (<a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>). Restricting the analyses to <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>, the two RCTs that did not show substantial heterogeneity, increased the overall effect size of oestrogen implants or patches, but otherwise did not appreciably change the main findings for the primary outcome. </p> </section> <section id="CD010503-sec-0127"> <h6 class="title">Adopting a random‐effects model</h6> <p>Pooling of studies was only used for evaluating implants or patches. Use of a random‐effects model rather than a fixed‐effect model to pool the three RCTs did not appreciably change the main findings. </p> </section> <section id="CD010503-sec-0128"> <h6 class="title">Using OR rather than RR as a summary measure</h6> <p>Use of odds ratios (ORs) instead of risk ratios (RRs) did not affect the results other than the obvious difference in value between the OR and RR. </p> </section> </section> <section id="CD010503-sec-0129"> <h5 class="title">Funnel plot</h5> <p>There were too few studies to produce a funnel plot.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010503-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010503-sec-0130"></div> <section id="CD010503-sec-0131"> <h3 class="title" id="CD010503-sec-0131">Summary of main results</h3> <section id="CD010503-sec-0132"> <h4 class="title">Effectiveness of oestrogen</h4> <p>This review found one small cross‐over study (n = 11) that compared oral luteal‐phase oestrogen versus placebo. Data were very low quality and unsuitable for analysis, but study authors reported that the intervention was ineffective and might aggravate the symptoms of PMS. </p> <p>This review found some very low quality evidence that continuous oestrogen combined with progestogen improves global symptoms compared to placebo. The pooled SMD for the effect of continuous oestrogen (patch or implant) on the symptoms of PMS favoured oestrogen over placebo. This applies both to global symptoms and specific symptoms. The overall effect size was small to medium (SMD = 0.34). No evidence was found that quality of life differed between women using continuous oestrogen or placebo. </p> <p>Finally, one study was found investigating the effect of oestrogen dosage (100 µg vs 200 µg). Data were of very low quality, and there was insufficient evidence to determine whether dosage affected global or specific PMS symptoms, quality of life or patient satisfaction. </p> </section> <section id="CD010503-sec-0133"> <h4 class="title">Adverse Events</h4> <p>The one trial on oral luteal‐phase oestrogen found no adverse effects, but the quality of evidence was very low due to the very small number of women studied (n = 11). </p> <p>The four trials on continuous oestrogen combined with progestogen reported a wide range of side effects. There was insufficient evidence to determine a difference in adverse event rates between oestrogen (implant or patch) plus progestogen and placebo. However, the quality of evidence was very low, mainly due to the small sample size and a lack of long‐term follow‐up. </p> <p>The evidence suggesting that oestrogen patch dose may affect adverse effect rates was also of very low quality. The trial comparing 100 µg versus 200 µg oestrogen patches found a lower overall risk of adverse effects in the lower‐dose group. </p> </section> </section> <section id="CD010503-sec-0134"> <h3 class="title" id="CD010503-sec-0134">Overall completeness and applicability of evidence</h3> <p>There have been no further published studies since 2001, perhaps because clinicians who prescribe oestrogen think that sufficient evidence for the effectiveness of oestrogen is already available. However, a more important reason may be that the pharmaceutical industry sees insufficient commercial potential, particularly outside the UK. Ideally, a large multicentre study should be conducted based on up‐to‐date diagnostic criteria using validated quantification methods. </p> <p>Very low quality evidence suggested that oral luteal‐phase oestrogen was ineffective (or even harmful) whereas continuous oestrogen plus progestogen was effective. A regimen of oestrogen without progestogen can only be sustained by administering oestrogen periodically, during the luteal phase. Luteal phase delivery of oestrogen will however not suppress ovulation, which may explain why women using oral luteal‐phase oestrogen did not report a beneficial effect on PMS symptoms. On the other hand, if oestrogen is to be administered continuously, progestogen must be added to protect the endometrium. </p> <p>All four trials of oestrogen plus progestogen alluded to the possible negative effects of oral progestogen, which was used in the trials to protect the endometrium but can cause PMS‐like side effects, reducing treatment efficacy. Indeed, we noted withdrawals from trials due to the side effects of oral progestogen. Unfortunately none of the studies systematically evaluated these side effects, even though they are commonly encountered in clinical practice. In an attempt to overcome the PMS‐like side effects, <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> used a lower dose (1 mg instead of the usual 5 mg) of oral norethisterone than the dose used in the other two trials of continuous oestrogen (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). However, the low heterogeneity with respect to adverse effects in these three RCTs suggests that this strategy may not influence the rate of adverse effects and therefore no evidence of its success was found. </p> <p>Interestingly, when oestrogen is used in hormone therapy (HT), progestogens are normally prescribed for 10 to 14 days each month to protect the endometrium. However, a Cochrane Review concluded that smaller doses of progestogens during HT may provide adequate protection of the endometrium (<a href="./references#CD010503-bbs2-0035" title="RobertsHE , HickeyM , LethabyA . Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: A Cochrane review summary. Maturitas2014;77(1):4‐6. [A Cochrane review summary. Maturitas,] ">Roberts 2014</a>). One trial of continuous oestrogen in this review (<a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>) prescribed the normal duration of 10 days' progestogen but <a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a> prescribed only 7 to 8 days of progestogen. Whether or not such differences in duration of progestogens will affect the risk of endometrial hyperplasia or the risk of other adverse side effects is unknown. Clearly, further research should be aimed at investigating the optimal dose of progestogens in order to minimize the occurrence of PMS‐like symptoms while still protecting the endometrium. </p> <p>Using an intrauterine releasing system for progesterone/progestogens instead of oral progestogens for endometrial protection may overcome the problem of PMS‐like side effects and is commonly used in the clinical arena. We found one conference abstract comparing the two methods (<a href="./references#CD010503-bbs2-0008" title="DomoneyC , PanayN , HawkinsA , StuddJ . Treatment of premenstrual syndrome with transdermal oestrogen. International Journal of Gynaecology &amp; Obstetrics2003;83(suppl 3):37‐8. ">Domoney 2003</a>). In this RCT, 37 women who all received transdermal oestradiol patches were randomized to intrauterine progesterone (n = 18) or oral progestogen (n = 19). None of the women in the intrauterine group dropped out due to PMS‐like side effects whereas six women in the oral group did. This provides some evidence to suggest that use of intrauterine progesterone reduces progestagenic PMS‐like side effects, but it is not conclusive. </p> <p>We searched trial databases and contacted other researchers and relevant drug manufacturers concerning ongoing or past unreported clinical trials of non‐contraceptive oestrogen management for ovulation suppression, and there appeared to be no unreported or ongoing studies. We have received information from one manufacturer (Bayer AG, Leverkussen, Germany), who trialled the use of a levonorgestrel‐releasing intrauterine system (LNG‐IUS) for endometrial protection during oestrogen replacement therapy in postmenopausal women, which led to its licensing for use as the progestogen component of hormone therapy. However, there are no published or ongoing efficacy and safety studies concerning the use of LNG‐IUS for endometrial protection under the higher doses required for ovulation suppression in PMS. </p> <p>Future clinical trials of the efficacy or effectiveness of continuous oestrogen should therefore include an arm comparing methods to administer progestogen. </p> </section> <section id="CD010503-sec-0135"> <h3 class="title" id="CD010503-sec-0135">Quality of the evidence</h3> <p>The three trials comparing oestrogen plus progestogen versus placebo were at low risk of bias in most domains, though two had a high level of attrition. The trial comparing oestrogen versus placebo was very small (n = 11), reporting of methods was poor and it did not use a validated measure, which meant we could only provide a narrative review. The trial comparing two oestrogen dosages, an open label study, was at high risk of bias in four areas (selection, performance, detection and attrition). All trials reported the number of participants lost to follow‐up; and for all an ITT or a modified ITT analysis was available. We had no evidence of selective outcome reporting by any of the studies. Finally, all four trials in this review reporting on continuous oestrogen (<a href="./references#CD010503-bbs2-0002" title="MagosAL , BrincatM , StuddJW . Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal1986;292(6536):1629‐33. [PUBMED: 3087550] ">Magos 1986</a>; <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0004" title="SmithRN , StuddJW , ZambleraD , HollandEF . A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology1995;102(6):475‐84. [PUBMED: 7632640] ">Smith 1995</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>), contributing 247 of the 258 women, were from a single centre (King's College Hospital in London). This potentially limits the external validity of the evidence. </p> <p>The overall quality of the evidence for the main findings was graded as very low using the GRADE criteria, due to serious risk of bias (related mostly to high attrition rates), imprecision due to the small total sample size and statistical and clinical heterogeneity (I² = 54%) in the comparison of oestrogen plus progestogen versus placebo. </p> </section> <section id="CD010503-sec-0136"> <h3 class="title" id="CD010503-sec-0136">Potential biases in the review process</h3> <p>Efforts were made to retrieve all eligible studies. The studies we found were at least 15 years old, including one only reported in the public literature as a conference abstract. To reduce the risk that we might miss an unpublished study, we contacted all pharmaceutical companies that produce oestrogen tablets, patches or implants for information about unreported past or ongoing trials, They all said there were no such trials, but we cannot exclude that unreported past trials exist because trial databases did not exist or were in their infancy more than 15 years ago. </p> <p>A specific issue was the use of a cross‐over trial design in three studies: <a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a> and <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>, comparing oestrogen plus progestogen versus placebo; and the single trial comparing oestrogen alone versus placebo (<a href="./references#CD010503-bbs2-0001" title="DharV , MurphyBE . Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology1990;15(5‐6):489‐93. ">Dhar 1990</a>). The ISPMD Montreal Consensus agreed that randomized trials of premenstrual disorders should ideally have a parallel design (<a href="./references#CD010503-bbs2-0031" title="O'BrienS , RapkinA , DennersteinL , NevatteT . Diagnosis and Management of Premenstrual Syndrome. BMJ2011;342:d2994. ">O'Brien 2011</a>), suggesting these trials were not ideal. Their main risks would be the potential for carry‐over effects from one period to the next; and an increased risk of attrition, specifically attrition after phase 1 of the trial, preventing women entering phase 2 (<a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). One trial provided month‐by‐month graphical data, which strongly suggested that the effect of the active treatment had disappeared in the month after the transition from active to placebo (<a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). We did therefore consider 3‐month results as valid endpoints for a cross‐over trial in this review, but note that the support for it is small. Overall, we therefore considered all cross‐over trials as having an unclear risk of other bias. Dropouts and loss to follow‐up occurred in two of the three cross‐over trials but almost all occurred within phase 1 of the trials and therefore no reasons were found to suspect they would cause a systematic difference between the two trial phases (<a href="./references#CD010503-bbs2-0003" title="PanayN , ReesM , DomoneyC , ZakariaF , GuilfordS , StuddJW . A multicentre double‐blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal2001;7(Suppl 3):19‐20. ">Panay 2001</a>; <a href="./references#CD010503-bbs2-0005" title="WatsonNR , StuddJWW . Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet1989;334(8665):730‐2. ">Watson 1989</a>). Overall, we considered this study design suitable for the current review and included data from both periods, which we analyzed as if they were from a parallel trial (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>, section 16.4.5). Our main reason for doing so was that two of the three trials did not provide sufficient data to allow a paired analysis, which would have been the preferred way to incorporate the data (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>, section 16.4.4). Our chosen method results in confidence intervals that are too wide, with the net effect that the cross‐over trial will be under‐weighted in the final analysis and clinically important heterogeneity may be disguised (<a href="./references#CD010503-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a> section 16.4.5). However, we believe a correct analysis would not have affected the reasons for grading the overall quality of the evidence as very low. </p> </section> <section id="CD010503-sec-0137"> <h3 class="title" id="CD010503-sec-0137">Agreements and disagreements with other studies or reviews</h3> <p>All oestrogen studies have been evaluated in this review and we identified no other systematic review of this topic. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010503-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010503-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010503-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010503-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.1 Symptom scores." data-id="CD010503-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.1 Symptom scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events." data-id="CD010503-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 1 Symptom scores." data-id="CD010503-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 1 Symptom scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 2 Withdrawal due to adverse events." data-id="CD010503-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 2 Withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 3 Specific adverse events (E+P versus placebo)." data-id="CD010503-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 3 Specific adverse events (E+P versus placebo). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 4 Specific symptoms of PMS: psychological." data-id="CD010503-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 4 Specific symptoms of PMS: psychological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 5 Specific symptoms of PMS: physical." data-id="CD010503-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 5 Specific symptoms of PMS: physical. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 6 Quality of life (E+P versus placebo)." data-id="CD010503-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 6 Quality of life (E+P versus placebo). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 1 Symptoms score: maximum mean daily PDQ." data-id="CD010503-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 1 Symptoms score: maximum mean daily PDQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 2 Adverse events." data-id="CD010503-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 3 Specific symptoms of PMS." data-id="CD010503-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 3 Specific symptoms of PMS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 4 VAS Sense of wellbeing." data-id="CD010503-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 4 VAS Sense of wellbeing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010503-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/urn:x-wiley:14651858:media:CD010503:CD010503-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_t/tCD010503-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 5 Patient satisfaction." data-id="CD010503-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 5 Patient satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/media/CDSR/CD010503/image_n/nCD010503-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010503-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oestrogen in combination with progestogen (sequential or continuous) compared to placebo for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oestrogen in combination with progestogen (sequential or continuous) compared to placebo. for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> continuous oestrogen (implant or patch) plus progestogen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen in combination with progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom scores</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The difference in the mean change from baseline in symptom scores suggested a small to moderate benefit in the oestrogen group (SMD 0.27 lower, 95% CI 0.47 lower to 0.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 women, effective sample size 267 women considering cross‐over trials<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (20 to 122) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/> (0.26 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 women, effective sample size 284 women considering cross‐over trials<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific adverse events</p> <p>over 2 to 4 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two RCTs (total 206 women) assessed one or more of nine specific adverse events and all findings were inconclusive. Events assessed were bleeding, breast tenderness, headache, nausea, weight gain, dysmenorrhoea, skin irritation, skin reaction and skin pigmentation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Includes cross‐over trial(s), with cross‐over at 3 or 4 months </p> <p><sup>2</sup>Downgraded one level for serious risk of bias: poor reporting of methods in one study and/or high attrition, includes one or more cross‐over studies with unclear risk of carry‐over effects </p> <p><sup>3</sup>Downgraded one level for serious inconsistency: I² = 63% </p> <p><sup>4</sup>Downgraded one level for questionable applicability: one of the studies administered progestogen in both arms </p> <p><sup>5</sup> Downgraded one level for serious imprecision: very few events and/or wide confidence intervals compatible with benefit in one or both arms or with no clinically meaningful effect </p> <p><sup>6</sup>Downgraded two levels for very serious imprecision: very few events and/or very wide confidence intervals compatible with benefit in one or both arms or with no clinically meaningful effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oestrogen in combination with progestogen (sequential or continuous) compared to placebo for controlling symptoms of premenstrual syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010503-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> luteal‐phase oestrogen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global symptoms of PMS</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The study authors reported that luteal‐phase oestrogen had a large negative effect on overall symptoms compared to placebo (P &lt; 0.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 women, effective sample size 22 women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events:</p> <p>withdrawal due to adverse events</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No withdrawals occurred in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 women, effective sample size 22 women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific adverse events</p> <p>over 3 menstrual cycles<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The study authors reported that "no significant adverse events were encountered".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 women,effective sample size 22<br/> women considering this was a cross‐over trial (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Cross‐over study with 11 women, but analyzed as a parallel trial (hence 22 participants). Women had 3 cycles in each arm. </p> <p><sup>2</sup> Downgraded two levels for very serious risk of bias: poor reporting of methods, no data suitable for analysis as used non‐validated scales </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision: tiny sample size (but no further downgrading possible) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010503-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women diagnosed with symptoms of premenstrual syndrome (PMS)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> oestrogen 100 µg patch plus progestogen<br/> <b>Comparison:</b> oestrogen 200 µg patch plus progestogen </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 200 µg patch plus progestogen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oestrogen 100 µg patch plus progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms score: Premenstrual Daily Questionnaire (PDQ)</p> <p>Scale from 0 to 30, with a higher score indicating a worse outcome</p> <p>over 8 months follow up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The difference in the change from baseline in the PDQ score was too imprecise to determine whether dosage had an effect on global symptoms (MD 1.55 lower, 95% CI 8.88 lower to 5.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ withdrawal rates</p> <p>over 8 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (87 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.34 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ specific side effects attributed to oestrogen</p> <p>over 8 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (92 to 349) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.51<br/> (0.26 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious risk of bias: unblinded, high attrition </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision: wide confidence intervals consistent with benefit in one or both arms or with no clinically meaningful effect from the intervention (however no further downgrading possible) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/full#CD010503-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010503-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oestrogen in combination with progestogen (sequential or continuous) versus placebo.</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptom scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.47, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 E+P versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.40, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 E+P versus placebo +P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.18, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 E+P versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 E+P versus placebo +P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.16, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific adverse events (E+P versus placebo) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Bleeding problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.10, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.87, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.55, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.65 [0.67, 202.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.78, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Skin irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.39, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Skin reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Skin pigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.0 [0.65, 186.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific symptoms of PMS: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.79 [‐1.17, ‐0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 E+P versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.90, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 E+P versus placebo +P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐1.71, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Specific symptoms of PMS: physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.98, ‐0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 E+P versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.86, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 E+P versus placebo +P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.36, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life (E+P versus placebo) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 VAS for feeling unwell (change from baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.90 [‐22.60, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 General health questionnaire (change from baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐9.98, 3.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oestrogen in combination with progestogen (sequential or continuous) versus placebo.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010503-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptoms score: maximum mean daily PDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.55 [‐8.88, 5.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Withdrawal rates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.34, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Side effects attributed to oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific symptoms of PMS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Psychological symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐1.17, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Physical symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐1.17, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 VAS Sense of wellbeing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐19.43, 22.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Patient satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.85, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010503.pub2/references#CD010503-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010503.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010503-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010503-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010503-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010503-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010503-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ro#CD010503-note-0012">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD010503-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010503-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010503\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010503\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010503\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010503\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010503\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010503.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010503.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010503.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010503.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010503.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720282888"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010503.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720282892"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010503.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfd5f39449377',t:'MTc0MDcyMDI4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 